Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus

The new quinolone garenoxacin (BMS-284756), which lacks a C-6 fluorine, was examined for its ability to block the growth of Staphylococcus aureus. Measurement of the MIC and the mutant prevention concentration (MPC) revealed that garenoxacin was 20-fold more potent than ciprofloxacin for a variety o...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Zhao, Xilin, Eisner, William, Perl-Rosenthal, Nathan, Kreiswirth, Barry, Drlica, Karl
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 2003
Assuntos:	Mechanisms of Resistance
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC149307/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12604537/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.3.1023-1027.2003
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!